The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 1.40
High: 1.40
Low: 1.40
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Installation at Barrow Neurological Institute

11 Dec 2018 07:00

RNS Number : 9988J
IQ-AI Limited
11 December 2018
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® installation at Barrow Neurological Institute

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Barrow Neurological Institute: Dignity Health, St. Joseph's Hospital and Medical Center ("BNI") has installed a new IB Rad Tech software platform to help assess treatment response for patients with brain tumors. BNI has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. IB Rad Tech was chosen for its ability to efficiently generate quantitative maps of enhancing regions of tumor (Delta T1) and fractional tumor burden ("FTB"). IB's perfusion-derived FTB maps have been shown to aid clinicians in distinguishing tumor from non-tumor tissue.

IB Rad Tech offers customised workflows that automate the generation of sophisticated maps, outputs quality assurance indices, and can allow manual acknowledgement and intervention during intermediate processing steps. For example, one workflow used in generating quantitative Delta T1 and FTB maps relies on an exclusive machine-learned calibration technology termed "standardisation", which works for all platforms and field strengths. This step has proven superior to conventional normalisation techniques as it eliminates the need for the manual placement of regions of interest (ROIs) by radiology staff or physicians thereby reducing error and improving workflow efficiencies.

David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well."

"Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

Barrow Neurological Institute / Dignity Health St. Joseph's Hospital and Medical Center has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. Since 1962, Barrow has grown into one of the premiere destinations in the world for neurology and neurosurgery. Experienced, highly skilled, and comprehensive teams of neurological specialists provide a complete spectrum of care-from diagnosis through outpatient neurorehabilitation-under one roof. Barrow Neurological Institute: Discover. Educate. Heal.

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides -visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

IQ-AI Limited (Ticker:IQAI) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.iq-ai.ltd).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGGGUAPUPRGWU
Date   Source Headline
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.